DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ovarian Cancer; Primary Peritoneal Serous Cancer; Fallopian Tube Cancer

Intervention: bevacizumab (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Beth Israel Deaconess Medical Center

Official(s) and/or principal investigator(s):
Panagiotis Konstantinopoulos, MD, PhD, Principal Investigator, Affiliation: Beth Israel Deaconess Medical Center


The purpose of this study is to evaluate how the participant's disease (ovarian, primary peritoneal serous, fallopian tube, or papillary serous endometrial cancer) responds to additional treatment with Avastin (bevacizumab). Participants have already received Avastin as part of maintenance therapy for their cancer. Maintenance therapy is a medical therapy that is given to people to prevent a relapse. However, cancer may return after maintenance therapy. This research study hopes to determine whether additional treatment with Avastin will be effective in treating the participant's cancer.

Clinical Details

Official title: Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Clinical Response Rate

Clinical Benefit Response Rate

Detailed description: OBJECTIVES: Primary: To determine the activity of bevacizumab in patients with epithelial ovarian, primary peritoneal serous, papillary serous endometrial or fallopian tube cancer who relapse after achieving an initial complete response to first-line therapy that included at least 6 month bevacizumab maintenance as defined by: 1) clinical response rate OR 2) clinical benefit response Secondary:

- To assess duration of progression free survival (PFS)

- To assess the safety

- To correlate response with the Avastin-free interval

STATISTICAL DESIGN: This study used a two-stage design to evaluate efficacy of bevacizumab based on a patient achieving either clinical response or clinical benefit response. The null and alternative response rates were 10% and 30%. If two or more patients enrolled in the stage one cohort (n=10 patients) achieved response than accrual would proceed to stage two (n=19 patients). If response was achieved by at least 6 patients in the final set of 29 evaluable patients then bevacizumab would be deemed worthy for further study. This design had 80% power given one-sided 0. 05 significance level.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Histologically or cytologically confirmed epithelial ovarian cancer, primary

peritoneal serous cancer, papillary serous endometrial cancer, or fallopian tube cancer

- Must have responded and remained clinically stable (as defined by normal clinical

examination, normal serum CA125 level and normal CT scan) after first-line platinum-based regimen followed by bevacizumab maintenance therapy

- Must have developed relapsed disease at least 3 months after completion of

bevacizumab maintenance therapy as defined by a) development of new, measurable lesions by RECIST criteria, but no lesion with maximum diameter greater than 3 centimeters OR b) newly elevated CA125 level at least 2 x ULN on 2 separate occasions, obtained at least 1 day but not more than 3 months apart

- ECOG Performance Status 0-2

- No prior cytotoxic chemotherapy or biologic therapy for disease recurrence allowed

- Prior hormonal-based therapy for ovarian, primary peritoneal serous or fallopian tube

cancer is allowed

- Toxic side effects related to prior chemotherapy or hormonal therapy must have

resolved to grade one or less or to baseline before initiation of bevacizumab

- 18 years of age or older

- Life expectancy of 6 months or greater

- Normal organ and marrow function as outlined in the protocol

Exclusion Criteria:

- Prior cytotoxic chemotherapy or biologic therapy for disease recurrence

- Known CNS disease, except for treated brain metastasis

- Pregnancy or breast feeding

- Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing

or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days

prior to day 0, or anticipation of need for major surgical procedure during the course of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular

device, within 7 days prior to enrollment

- History of abdominal fistula, GI perforation, intra-abdominal abscess, or CT evidence

of bowel obstruction or bowel wall thickening

- Symptoms of intestinal obstruction, or requirement of parenteral hydration and/or


- History of active malignancy during the last 3 years, except non-melanomatous skin

cancer or in situ breast or cervical cancer

- Evidence of preexisting uncontrolled hypertension. If patient has hypertension, it

must be medically controlled (< 150/90) prior to starting bevacizumab

- Proteinuria at screening

- Dementia or significantly altered mental status that would prohibit the understanding

and/or giving of informed consent

- Therapeutic anticoagulation is not by itself and exclusion criterion. However, for

certain high risk patients on therapeutic anticoagulation, eligibility will be determined after discussion with the overall PI

- Any active bleeding

- Serious, non-healing wound, ulcer, or bone fracture

- Prior history of hypertensive crisis or hypertensive encephalopathy

- NYHA Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to Day 1

- History of stroke or transient ischemic attack within 6 months prior to day 1

- Significant vascular disease within 6 months prior to day 1

- History of hemoptysis within 1 month prior to day 1

- Presence of measurable lesion(s) by RECIST criteria with maximum diameter greater

than 3 centimeters

Locations and Contacts

Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States

Massachusetts General Hospital, Boston, Massachusetts 02114, United States

Additional Information

Starting date: March 2009
Last updated: April 13, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017